Knight Therapeutics Inc.
TSX:GUD.TODrug Manufacturers - Specialty & Generic
+$0.07 today
- Market cap
- $1.14B
- Beta
- 0.07
- P/E (TTM)
- 164.6
- EPS (TTM)
- $0.06
Volume 0.04M
Average 0.10M
Returns on capital
Knight Therapeutics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-0.7%
avg 1.1%
ROIC
-0.2%
avg -0.3%
ROA
-0.5%
avg 1.1%
Analysis
ROIC is currently the strongest return metric at -0.2% versus its period average of -0.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Samira Sakhia | President, Chief Executive Officer & Director | CAD 1.44M | 58 | — | — |
Arvind Utchanah | Chief Financial Officer | CAD 1.12M | — | — | — |
Amal Khouri | Chief Business Officer | CAD 1.06M | — | — | — |
Christine Poulin | General Manager of Canada | CAD 789.22K | — | — | — |
Jonathan Ross Goodman | Executive Chairman | CAD 528.44K | 57 | — | — |
Susan Caroline Emblem | Global Vice President of Human Resources | CAD 482.41K | — | — | — |
Monica Percario | Global Vice President of Regulatory & Quality | CAD 480.57K | — | — | — |
Henrique Dias | Global Vice President of Marketing | CAD 479.79K | — | — | — |
Leopoldo Bosano | Vice-President of Manufacturing & Operations | CAD 478.92K | — | — | — |
Melanie Groleau | Global Vice President of Medical & Clinical | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +15.3% | +7.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +15.3% over three years. Forward estimates point to Revenue at +7.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Knight Therapeutics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about GUD.TO's management, answered from reported figures.
Who manages GUD.TO?
Knight Therapeutics Inc. (GUD.TO) lists 10 active executives. The top listed executive is Amal Khouri, Chief Business Officer.
Continue the stock analysis
Jump to another research area for this company.